Skip to main
NAGE

ChromaDex Corp (NAGE) Stock Forecast & Price Target

ChromaDex Corp (NAGE) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Niagen Bioscience is a leader in NAD+ science and healthy-aging research, with a strong focus on precision science and innovative NAD+-boosting solutions. The company's recent financial results have shown moderate revenue outperformance, and they have multiple methods to drive future growth, including expanding into new markets and developing new products. The company also has a strong IP portfolio with over 100 patents and potential in multiple industries, including rare diseases. With the increasing global focus on health and wellness, Niagen Bioscience is well-positioned for long-term success.

Bears say

Niagen Bioscience is currently trading at a steep valuation and faces significant risks, including potential slower sales growth, unfavorable clinical data, adverse legal decisions, and geopolitical disruptions. Despite strong projected financials and attractive valuations compared to other supplement companies, recent stock performance and macro volatility suggest caution for potential investors. One-time gains from the sale of a subsidiary and the potential for future revenue from an AT opportunity may provide upside, but it remains to be seen if consumers will continue to prioritize health and wellness products during times of economic uncertainty.

ChromaDex Corp (NAGE) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ChromaDex Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ChromaDex Corp (NAGE) Forecast

Analysts have given ChromaDex Corp (NAGE) a Strong Buy based on their latest research and market trends.

According to 2 analysts, ChromaDex Corp (NAGE) has a Strong Buy consensus rating as of Sep 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ChromaDex Corp (NAGE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.